The majority of treatments granted a marketing authorisation without controlled study data have not been subject to economic evaluation in a published form, with a high level of non-submission to UK health technology agencies. The evaluations that have been performed were generally centred on naïve comparisons to historical controls from clinical trial arms (both randomised and non-randomised), or registry/case series data, which may not be appropriate.
Guidance is required on the appropriateness of historical controls and on the most relevant methods for modelling non-randomised data to estimate treatment effects. Ultimately formal guidance and standardisation may reduce bias in economic evaluations and lead to an improvement in the average quality of published models. A systematic review and taxonomy of economic evaluations of pharmaceuticals licensed on the basis of uncontrolled clinical studies 1. University College London, London, UK 2. BresMed, Sheffield, UK
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The search identified 3151 hits; see Table 2 for detailed breakdown. After primary screening a total of 74 economic evaluations were identified: 29 peer-reviewed articles, 15 ISPOR abstracts and 30 HTAs. Of the 98 submission documents identified, only 28 were for UK agencies. A large number of drugs granted a marketing authorisation without an RCT had not been evaluated in a published economic model (45 had models available, from a total of 75).
A taxonomy of the economic modelling approaches showed that the majority of approaches relied on the use of an 'historical control', with data from different sources describing outcomes in theoretically similar patients, see Figure 1 .
Of the 43 historical controls, 22 used comparisons to arms from other clinical trials -17 compared to the results of a single trial, and five compared to pooled or meta-analysed trial data. Despite potential differences between trials, only 7 of the 22 attempted to correct for any differences. A further 14 historically controlled models used registry data (5) or case series (9), despite concerns that patients in observational studies may be systematically different to those in clinical trials. Finally, seven historically controlled models were compared only to expert opinion, a clear limitation.
Of the approaches not using historical controls, three models could loosely be described as using the patient as their own control, taking the change from baseline as being due to the drug. Three models were cost minimisations, which have been extensively criticised in the literature. One model assumed a 'cumulative approach,' where patients who received the drug had benefit only for the time on treatment (and subsequent health states were unaffected), and one model was a threshold analysis, which looked at how effective the drug would need to be to show costeffectiveness relative to the comparator data. In this case the relative risk needed was clearly more favourable than all estimates, and the threshold analysis was effective in illustrating this.
Overall there was no consensus on how best to model uncontrolled studies. Whilst the historical control seems to be the main vehicle used, there was a large degree of variation in comparisons made and how data were adjusted (or not) for differences between trials. Clinical trial and observational data were used interchangeably, with only a few studies accounting for patient selection.
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Results

Conclusions
Literature search
We searched for models or HTAs listed in PubMed and the ISPOR scientific presentations database, as well as the websites for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG). The range of dates included was from January 1999 (the earliest date that the treatments included were licensed) to May 2014 (the date of the first search).
Each hit was screened for whether it contained a model. De-duplication of models was then performed; for example, where a model is described in a publication and used in an HTA or published in two different articles with different cost inputs for a country adaptation (but the same approach taken to modelling efficacy data).
Taxonomy
Following de-duplication, the models were categorised according to the approach taken to modelling comparative efficacy data. 
